-
Signature
-
/s/ Matthew K. Szot
-
Issuer symbol
-
CVKD
-
Transactions as of
-
24 Oct 2025
-
Transactions value $
-
-$50,364
-
Form type
-
4
-
Filing time
-
28 Oct 2025, 17:00:04 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Szot Matthew K |
Chief Financial Officer |
C/O CADRENAL THERAPEUTICS, INC.,, 822 A1A NORTH, SUITE 306, PONTE VEDRA, |
/s/ Matthew K. Szot |
28 Oct 2025 |
0001401385 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CVKD |
Common Stock |
Sale |
-$25.2K |
-1.8K |
-13.3% |
$13.99 |
11.7K |
24 Oct 2025 |
Direct |
F1 |
| transaction |
CVKD |
Common Stock |
Sale |
-$25.2K |
-1.8K |
-15.34% |
$13.99 |
9.93K |
27 Oct 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: